Checkpoint Therapeutics IncNASDAQ:CKPT
- LAST PRICE1.4371
- TODAY'S CHANGE (%)0.0171 (1.2042%)
- Bid / Lots1.4300/ 11
- Ask / Lots1.4500/ 10
- Open / Previous Close1.4200 / 1.4200
- Day Range
- 52 Week Range
- Volume29,673
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CKPT |
|---|---|---|
| 09:32 ET | 3270 | 1.44 |
| 09:34 ET | 277 | 1.44 |
| 09:38 ET | 200 | 1.43 |
| 09:45 ET | 450 | 1.44 |
| 09:48 ET | 2115 | 1.44 |
| 09:50 ET | 1000 | 1.43 |
| 09:52 ET | 300 | 1.439 |
| 09:54 ET | 300 | 1.44 |
| 09:57 ET | 12651 | 1.42 |
| 10:01 ET | 2000 | 1.43 |
| 10:03 ET | 875 | 1.435 |
| 10:08 ET | 1849 | 1.45 |
| 10:10 ET | 1000 | 1.4371 |
| 10:12 ET | 100 | 1.4371 |
Yesterday
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT, from 13 hours ago by Dow Jones
13 hours ago by Dow JonesLifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), bluebird bio, inc. (NASDAQ: BLUE), Sonder Holdings, Inc. (NASDAQ: SOND), and Ocugen Inc. (NASDAQ: OCGN), from 13 hours ago by Dow Jones
13 hours ago by Dow JonesDEADLINE ALERT for HRT, CKPT, and SOND: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders, from 22 hours ago by Dow Jones
22 hours ago by Dow Jones
Apr 24, 2024
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT, from 10:34PM ET on Wednesday Apr 24, 2024 by Dow Jones
10:34PM ET on Wednesday Apr 24, 2024 by Dow JonesBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder, and Perion and Encourages Investors to Contact the Firm, from 9:00PM ET on Wednesday Apr 24, 2024 by Dow Jones
9:00PM ET on Wednesday Apr 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Checkpoint Therapeutics Inc | 50.7M | -0.5x | --- |
ARCA Biopharma Inc | 50.5M | -9.7x | --- |
Gain Therapeutics Inc | 49.8M | -1.8x | --- |
Eledon Pharmaceuticals Inc | 50.1M | -1.1x | --- |
AVROBIO Inc | 53.2M | 4.4x | --- |
Intensity Therapeutics Inc | 53.8M | -4.4x | --- |
Company Information
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
Contact Information
- Headquarters
- 95 SAWYER ROAD, SUITE 110WALTHAM, MA, United States 02453
- Phone
- 781-652-4500
- Fax
- 302-531-3150
Executives
- Chairman of the Board
- Michael Weiss
- President, Chief Executive Officer, Director
- James Oliviero
- Chief Financial Officer, Treasurer, Corporate Secretary
- William Gray
- Director
- Lindsay Rosenwald
- Independent Director
- Christian Bechon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.7M |
|---|---|
Revenue (TTM) | $103.0K |
Shares Outstanding | 35.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-2.93 |
Book Value | $-0.47 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 492.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -50,629.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
